SRC - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
INSR	insulin receptor	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling	Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate NN344 AT1391 Linsitinib [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Chromic chloride Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Fostamatinib Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Leprechaunism ; Donohue syndrome Rabson-Mendenhall syndrome
ITGB3	integrin subunit beta 3	Platelet degranulation Elastic fibre formation PECAM1 interactions Molecules associated with elastic fibres Integrin cell surface interactions Integrin cell surface interactions TGF-beta receptor signaling activates SMADs Syndecan interactions Syndecan interactions ECM proteoglycans Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway Signal transduction by L1 MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Mechanical load activates signaling by PIEZO1 and integrins in osteocytes Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	Abciximab Eptifibatide Antithymocyte immunoglobulin (rabbit) Levothyroxine Tirofiban Resveratrol Lefradafiban LM-609 Fradafiban Ferric maltol	Allograft rejection Glanzmann thrombasthenia
ITK	IL2 inducible T cell kinase	Generation of second messenger molecules FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization	Staurosporine Pazopanib Fostamatinib Zanubrutinib
JUP	junction plakoglobin	Adherens junctions interactions VEGFR2 mediated vascular permeability Neutrophil degranulation Keratinization Formation of the cornified envelope RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOJ GTPase cycle Regulation of CDH11 function Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane CDH11 homotypic and heterotypic interactions	Zinc Zinc acetate	Naxos disease and Carvajal syndrome Arrhythmogenic right ventricular cardiomyopathy (ARVC)
KCNA5	potassium voltage-gated channel subfamily A member 5	Voltage gated Potassium channels Phase 3 - rapid repolarisation	Enflurane Promethazine Miconazole Vernakalant Dalfampridine Isavuconazole	Atrial fibrillation
KCNB1	potassium voltage-gated channel subfamily B member 1	Voltage gated Potassium channels Glucagon-like Peptide-1 (GLP1) regulates insulin secretion	Enflurane Promethazine Miconazole Dalfampridine
KCNQ5	potassium voltage-gated channel subfamily Q member 5	Voltage gated Potassium channels	Enflurane Gabapentin Promethazine Miconazole Ezogabine ICA-105665
KDR	kinase insert domain receptor	Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization Integrin cell surface interactions VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway VEGFR2 mediated cell proliferation Signaling by membrane-tethered fusions of PDGFRA or PDGFRB High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Sorafenib Sunitinib 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea Cediranib Vatalanib XL999 TG-100801 XL820 CYC116 Ramucirumab Pegdinetanib RAF-265 Linifanib IMC-1C11 Semaxanib Pazopanib Midostaurin Axitinib 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine Cabozantinib Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Fostamatinib Erdafitinib Foretinib Ripretinib Pralsetinib Olinvacimab
KHDRBS1	KH RNA binding domain containing, signal transduction associated 1	PTK6 Regulates Proteins Involved in RNA Processing
KIFAP3	kinesin associated protein 3	Translocation of SLC2A4 (GLUT4) to the plasma membrane MHC class II antigen presentation Intraflagellar transport COPI-dependent Golgi-to-ER retrograde traffic Kinesins Kinesins
KIT	KIT proto-oncogene, receptor tyrosine kinase	PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Regulation of KIT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Dasatinib-resistant KIT mutants Imatinib-resistant KIT mutants KIT mutants bind TKIs Masitinib-resistant KIT mutants Nilotinib-resistant KIT mutants Regorafenib-resistant KIT mutants Signaling by kinase domain mutants of KIT Sunitinib-resistant KIT mutants Signaling by juxtamembrane domain KIT mutants Sorafenib-resistant KIT mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by extracellular domain mutants of KIT Transcriptional and post-translational regulation of MITF-M expression and activity Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Sorafenib Imatinib Dasatinib Sunitinib Phosphonotyrosine Nilotinib XL820 OSI-930 Linifanib Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Ancestim Tivozanib Fostamatinib Erdafitinib Amuvatinib Pexidartinib Ripretinib Avapritinib	Acute myeloid leukemia (AML) Piebaldism
LATS2	large tumor suppressor kinase 2	Signaling by Hippo
LRP1	LDL receptor related protein 1	Scavenging of heme from plasma Retinoid metabolism and transport	Antihemophilic factor, human recombinant Tenecteplase Coagulation Factor IX (Recombinant) Lanoteplase Von Willebrand factor human Coagulation Factor IX Human Lonoctocog alfa Moroctocog alfa
MAP2	microtubule associated protein 2		Estramustine Paclitaxel Docetaxel
MAP2K1	mitogen-activated protein kinase kinase 1	MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants	K-252a 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide Mirdametinib N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib Selumetinib Pimasertib	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
MAPK15	mitogen-activated protein kinase 15		Acetylsalicylic acid Minocycline Colforsin Fostamatinib
MAPK3	mitogen-activated protein kinase 3	MAPK3 (ERK1) activation RAF-independent MAPK1/3 activation ISG15 antiviral mechanism Signaling by NODAL Spry regulation of FGF signaling Signaling by Activin Frs2-mediated activation ERK/MAPK targets ERK/MAPK targets ERKs are inactivated Regulation of actin dynamics for phagocytic cup formation Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Oncogene Induced Senescence FCERI mediated MAPK activation Regulation of HSF1-mediated heat shock response NCAM signaling for neurite out-growth RSK activation Signal transduction by L1 Activation of the AP-1 family of transcription factors Thrombin signalling through proteinase activated receptors (PARs) Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate NADPH Oxidases RAF/MAP kinase cascade MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RNA Polymerase I Promoter Opening Signal attenuation Interferon gamma signaling Advanced glycosylation endproduct receptor signaling Gastrin-CREB signalling pathway via PKC and MAPK ESR-mediated signaling RUNX2 regulates osteoblast differentiation Regulation of PTEN gene transcription Regulation of the apoptosome activity Estrogen-dependent nuclear events downstream of ESR-membrane signaling Suppression of apoptosis Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants FCGR3A-mediated phagocytosis Nuclear events stimulated by ALK signaling in cancer IFNG signaling activates MAPKs Negative Regulation of CDH1 Gene Transcription NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes Growth hormone receptor signaling Signaling by LTK in cancer Transcriptional and post-translational regulation of MITF-M expression and activity	Sulindac Acetylsalicylic acid Minocycline Arsenic trioxide Colforsin Purvalanol 5-iodotubercidin Seliciclib Cholecystokinin Ulixertinib
MAPK8IP3	mitogen-activated protein kinase 8 interacting protein 3
MAPRE1	microtubule associated protein RP/EB family member 1	Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane RHO GTPases Activate Formins Mitotic Prometaphase The role of GTSE1 in G2/M progression after G2 checkpoint AURKA Activation by TPX2 EML4 and NUDC in mitotic spindle formation
MAPT	microtubule associated protein tau	Caspase-mediated cleavage of cytoskeletal proteins	Lansoprazole Astemizole Paclitaxel Docetaxel Flortaucipir F-18	Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3) Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease

Search Results for: SRC